Table 3.
NcRNA-regulated AS events involved in drug resistance in cancer
| NcRNA | Mechanism | Target genes | Biology function | Drugs | Related diseases | Refs |
|---|---|---|---|---|---|---|
| UCA1 | targets miR-184 and up-regulates SF1 expression | Mcl pre-mRNA → Mcl-1L | increases BCL2 protein expression | Cisplatin | Oral squamous cell carcinoma | 80, 83 |
| miR-193a-3p | reduces SRSF2 expression | BCL-X, caspase 9 pre-mRNA → BCL-XL, caspase 9a | suppresses cell apoptosis | Cisplatin | Gastric cancer | 81 |
| Fas-AS1 | low levels of it promote RBM5-mediated AS | Fas pre-mRNA → sFas | causes impaired Fas signaling in chemoresistance | Cytotoxic drugs | B-cell lymphoma | 82, 85 |
| CRNDE | interacts with SRSF6 and reduces its stability | PICALM pre-mRNA → PICALML (-) | reduces autophagy flux | 5-FU/oxaliplatin | Gastric cancer | 87 |
| EGOT | forms pre-ITPR1/EGOT dsRNA and recruits hnRNPH1 | ITPR1 pre-mRNA → ITPR1 | promotes autophagy to increase drug sensitivity | Paclitaxel | Breast cancer | 88 |
| miR-374B | decreases hnRNPA1 expression | PKM pre-mRNA → PKM2 (-) | antagonizes PKM2-mediated glycolysis pathway | Sorafenib | Hepatocellular carcinoma | 94 |
| CIRS-122 | targets miR-12 | PKM pre-mRNA → PKM2 | promotes glycolysis | Oxaliplatin | Colorectal cancer | 95 |
*(-) refers to down-regulated AS products of target genes.